DNA Vaccine for Shingles
HOME > Products > DNA Vaccine for Shingles (GLS-5100)
- Development background
One of the recently fast-growing "silver" medicines
- Incidence of 15~20% in global population; 67% in 50 years of age or older; continuously increasing with aging
- Nerve, eyes, skin, internal organ damage, and severe nerve pain after shingles (PHN, Post-herpetic Neuralgia).
- UK Health Authority recommends shingles vaccine injection in seniors between 70 and 79 years of age (2013).
Problems of existing shingles vaccine
- The only shingles vaccine available in the market, Zostavax, increases the potency by concentrating the
chickenpox vaccine (Varivax). This is not optimized for enhancing the CD8+ T-cell immune response
that is very critical to preventing shingles. The actual prevention rate is limited to 51%1).
- Zostavax, a live attenuated vaccine, cannot be administered to immunocompromised patients.
※ There is a need for a new shingles vaccine with high safety and efficacy in immunocompromised patients.
- Features and advantages of GLS-5100
Global leading shingles vaccine
- First-In-Class(first use of CD8+ CMI), Best-In-Class, latent varicella-zoster virus(VZV) elimination by
potent T-immune cell in adult patients of 55 years of age or older who are expected to take
Competitiveness compared to existing shingles vaccines (MSD, ZOSTAVAX®)
- Three antigens involved in virus latency selected and candidates determined (patent filing completed)
- Studies in experimental animals demonstrated potent T-cell immune response: high prevention rate expected
in the product development (currently in the level about 50%)
- With easy production at a large scale and stable vaccine supply, it can be a blockbuster product
(overcoming limitations of existing vaccines).
- 1) N Engl J med 2005, 352:2271-2284
- Difference of Shingles vaccines by platform
DNA vaccine platform Live attenuated vaccine platform Case GLS-5100 Zostavax Developer GeneOne Life Science, Inc. MSD Development state Under development
(in process of pre-clinical study)
Available in the market Use in
Allowed Not allowed Antibody response
+++ +++ CD4 T-cell
+++ +++ CD8 T-cell
+++ ++ Flexibility of
Critical antigens in VZV reactivation can be
There is no flexibility in antigen selection. Production capacity Produced with plasmid purification process
via large-scale E.coli fermentation
Limited production scale by using
concentrated chickenpox vaccine (Varivax)
- ++ : good +++ : very good